Population Pharmacogenomics in Croatia: Evaluating the PGx Allele Frequency and the Impact of Treatment Efficiency.
allele frequencies
drug-metabolizing enzymes
pharmacogenomics
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Aug 2023
31 Aug 2023
Historique:
received:
03
07
2023
revised:
24
08
2023
accepted:
28
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Adverse drug reactions (ADRs) are a significant cause of mortality, and pharmacogenomics (PGx) offers the potential to optimize therapeutic efficacy while minimizing ADRs. However, there is a lack of data on the Croatian population, highlighting the need for investigating the most common alleles, genotypes, and phenotypes to establish national guidelines for drug use. A single-center retrospective cross-sectional study was performed to examine the allele, genotype, and phenotype frequencies of drug-metabolizing enzymes, receptors, and other proteins in a random sample of 522 patients from Croatia using a 28-gene PGx panel. Allele frequencies, genotypes, and phenotypes for the investigated genes were determined. No statistically significant differences were found between the Croatian and European populations for most analyzed genes. The most common genotypes observed in the patients resulted in normal metabolism rates. However, some genes showed higher frequencies of altered metabolism rates. This study provides insights into the allele, genotype, and phenotype frequencies of drug-metabolizing enzymes, receptors, and other associated proteins in the Croatian population. The findings contribute to optimizing drug use guidelines, potentially reducing ADRs, and improving therapeutic efficacy. Further research is needed to tailor population-specific interventions based on these findings and their long-term benefits.
Sections du résumé
BACKGROUND
BACKGROUND
Adverse drug reactions (ADRs) are a significant cause of mortality, and pharmacogenomics (PGx) offers the potential to optimize therapeutic efficacy while minimizing ADRs. However, there is a lack of data on the Croatian population, highlighting the need for investigating the most common alleles, genotypes, and phenotypes to establish national guidelines for drug use.
METHODS
METHODS
A single-center retrospective cross-sectional study was performed to examine the allele, genotype, and phenotype frequencies of drug-metabolizing enzymes, receptors, and other proteins in a random sample of 522 patients from Croatia using a 28-gene PGx panel.
RESULTS
RESULTS
Allele frequencies, genotypes, and phenotypes for the investigated genes were determined. No statistically significant differences were found between the Croatian and European populations for most analyzed genes. The most common genotypes observed in the patients resulted in normal metabolism rates. However, some genes showed higher frequencies of altered metabolism rates.
CONCLUSIONS
CONCLUSIONS
This study provides insights into the allele, genotype, and phenotype frequencies of drug-metabolizing enzymes, receptors, and other associated proteins in the Croatian population. The findings contribute to optimizing drug use guidelines, potentially reducing ADRs, and improving therapeutic efficacy. Further research is needed to tailor population-specific interventions based on these findings and their long-term benefits.
Identifiants
pubmed: 37686303
pii: ijms241713498
doi: 10.3390/ijms241713498
pmc: PMC10487565
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Croat Med J. 2003 Aug;44(4):425-8
pubmed: 12950145
Clin Pharmacol Ther. 2017 Jul;102(1):37-44
pubmed: 27997040
Per Med. 2019 Mar;16(2):171-184
pubmed: 30484741
JAMA. 2012 Dec 26;308(24):2584-93
pubmed: 23268517
Expert Opin Drug Metab Toxicol. 2020 Oct;16(10):953-964
pubmed: 32726152
Croat Med J. 2022 Jun 22;63(3):257-264
pubmed: 35722694
Clin Pharmacol Ther. 2022 Nov;112(5):959-967
pubmed: 35034351
Mol Biol Rep. 2021 Jun;48(6):5181-5186
pubmed: 34215992
Pharmacogenomics J. 2010 Feb;10(1):1-11
pubmed: 19884908
Pharmgenomics Pers Med. 2008 Nov;2008(1):7-14
pubmed: 20622972
Pharmacogenomics. 2020 Jan;21(2):141-156
pubmed: 31950879
Lancet. 2013 Aug 31;382(9894):790-6
pubmed: 23755828
Pharmacogenomics. 2020 Jun;21(8):559-569
pubmed: 32301649
Clin Pharmacol Ther. 2022 May;111(5):1007-1021
pubmed: 35152405
Circ Genom Precis Med. 2018 Sep;11(9):e002228
pubmed: 30354330
Clin Pharmacol Ther. 2016 Jan;99(1):36-7
pubmed: 26094938
Clin Pharmacol Ther. 2014 Feb;95(2):141-6
pubmed: 24096968
Pharmacogenomics. 2023 Apr;24(5):243-246
pubmed: 37014361
Clin Pharmacol Ther. 2016 Apr;99(4):363-9
pubmed: 26417955
Clin Pharmacol Ther. 2023 Jul;114(1):51-68
pubmed: 37032427
Clin Pharmacol Ther. 2021 Oct;110(4):888-896
pubmed: 33387367
Per Med. 2018 May 1;15(3):209-221
pubmed: 29767545
Clin Pharmacol Ther. 2021 Jun;109(6):1417-1423
pubmed: 32770672
Croat Med J. 2022 Apr 30;63(2):117-125
pubmed: 35505645
Pharmacogenet Genomics. 2012 Jul;22(7):555-8
pubmed: 22407409
N Engl J Med. 2019 Oct 24;381(17):1621-1631
pubmed: 31479209
Clin Pharmacol Ther. 2019 May;105(5):1095-1105
pubmed: 30447069
Croat Med J. 2019 Jun 13;60(3):212-220
pubmed: 31187948
Clin Pharmacol Ther. 2020 Aug;108(2):191-200
pubmed: 32189324
Pharmacogenomics. 2010 Jun;11(6):781-91
pubmed: 20504253
J Neurol Sci. 2014 Aug 15;343(1-2):30-5
pubmed: 24974237
Pharmacogenomics. 2005 Jun;6(4):357-71
pubmed: 16004554
Clin Pharmacol Ther. 2018 Feb;103(2):210-216
pubmed: 29152729
Clin Pharmacol Ther. 2019 Oct;106(4):726-733
pubmed: 31006110
J Pers Med. 2023 Feb 26;13(3):
pubmed: 36983598
Arch Med Res. 2015 May;46(4):265-73
pubmed: 25989350